Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04535271 · ClinicalTrials.gov registry record · Phase 2
Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma
A Phase 2 study of Leiomyosarcoma, sponsored by Sarcoma Oncology Research Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT04535271: Recruiting Phase 2 study of Leiomyosarcoma, sponsored by Sarcoma Oncology Research Center.
NCT04535271 is a Phase 2 study of Leiomyosarcoma that is actively recruiting participants, run by Sarcoma Oncology Research Center. The registered enrollment target is 80 participants, below the 117-participant average among 16 other Leiomyosarcoma trials with a reported enrollment target (32% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04535271, a Phase 2 study of Leiomyosarcoma, is actively recruiting participants, sponsored by Sarcoma Oncology Research Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.
Primary Outcome
Progression free survival up to disease progression or death from any cause
Conditions Studied
Interventions
- DRUG Trabectedin
Study Locations (1)
California
- Sant P Chawla - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-09-09 |
| Est. Completion | 2029-03-30 |
| Phase | Phase 2 |
What NCT04535271 shows while recruiting
NCT04535271 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 117-participant average among 16 other Leiomyosarcoma trials with a reported enrollment target (32% lower).
The record links to 1 condition, with Leiomyosarcoma appearing as the primary indexed condition, and to 1 intervention - of which Trabectedin is the first listed.
NCT04535271 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04535271 about?
NCT04535271 is a clinical study titled "Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma". This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.
What is the current status of trial NCT04535271?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2021-09-09. Estimated completion is 2029-03-30.
What conditions does trial NCT04535271 study?
This clinical trial studies the following conditions: Leiomyosarcoma.
What interventions are being tested in trial NCT04535271?
The interventions under investigation include: Trabectedin (DRUG).
Who is sponsoring clinical trial NCT04535271?
This trial is sponsored by Sarcoma Oncology Research Center, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04535271 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leiomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04535271's enrollment target sits among peer trials
80 6th of 16 higher than 11 of 16 other Leiomyosarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leiomyosarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
RECRUITING · Phase 2
-
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Nivolumab in Selected Uterine Cancer Patients
COMPLETED · Phase 2
-
Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
COMPLETED · Phase 2
-
Bevacizumab and Radiation Therapy for Sarcomas
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI